http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-878622-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J75-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J75-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J5-00 |
| filingDate | 1958-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1961-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-878622-A |
| titleOfInvention | Improvements in or relating to steroids and the manufacture thereof |
| abstract | The invention comprises 6-fluoro-9a -halo-21-desoxyhydrocortisone and 6-fluoro-9a -halo-21-desoxycortisone, wherein the 9a -halogen atom is fluorine chlorine or bromine and compounds of the formulae: <FORM:0878622/IV (b)/1> wherein R is a hydrocarbon radical containing 1-10 carbon atoms, wherein R1 is a hydroxy or keto and X is fluorine chlorine or bromine, and the process of treating 6-fluoro-9a -halo- 11b ,17a ,21- trihydroxy-4- pregnene-3,20-dione with an alkyl or aryl sulphonyl halide to obtain the corresponding 21-alkyl or aryl sulphonate of 6-fluoro-9a -halo-11b , 17a ,21-trihydroxy-4-pregnene-3,20-dione, treating the thus produced 21-ester with an alkal metal iodide to obtain 6-fluoro-9a -halo-21-iodo-11b ,17a - dihydroxy-4- pregnene- 3, 20-dione which is reduced, e.g. with zinc dust, sodium thiosulphate, sodium bisulphite and potassium bisulphite to obtain 6-fluoro-9a -halo-11b ,17a - dihydroxy-4- pregnene- 3,20-dione. If desired the 11-hydroxy group may be oxidised to obtain 6-fluoro-9a -halo-17a -hydroxy - 4 - pregnene-3,11,20-trione. Alternatively the removal of the 21-hydroxyl group may precede the introduction of the 9-halo group. The process is applicable to both the 6a and 6b epimers the 6b -compound being epimerised to the 6a -compound by means of a mineral acid, e.g. hydrochloric acid. Illustrative products of the invention are 6a ,9a -difluoro-21-desoxyhydrocortisone, 6a -fluoro-9a -chloro-21-desoxyhydrocortisone, 6a -fluoro-9a -bromo-21-desoxyhydrocortisone, 6a ,9a -difluoro-21-desoxycortisone, 6a -fluoro-9a -chloro-21-desoxycortisone, 6a -fluoro-9a - bromo-21-desoxycortisone, 6a ,9a -difluoro-11b ,17a ,21-tri-hydroxy-4-pregnene-3,20-dione 21-methanesulphonate and 6a ,9a -difluoro-11b ,17a -dihydroxy-21-iodo - 4 - pregnene-3,20-dione. Specification 850,833 is referred to.ALSO:Pharmaceutical compositions comprise a 6-fluoro-9a -halo-21-desoxyhydrocortisone or a 6-fluoro-9a -halo-21-desoxycortisone and a pharmaceutical diluent. They are administered orally as pills, tablets, capsules, syrups and elixirs, in liquid forms for injectable products and topically as ointments, creams or lotions with or without coacting antibiotics, germicides and other materials. Specification 850,833 is referred to. |
| priorityDate | 1957-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.